Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I

A. D‘Urzo, E. Kerwin, J. Donohue, S. Rennard, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Toronto, Canada; Medford, Chapel Hill, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain)

Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Session: Trials in COPD: novel treatments and insights
Session type: Poster Discussion
Number: 2890
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. D‘Urzo, E. Kerwin, J. Donohue, S. Rennard, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Toronto, Canada; Medford, Chapel Hill, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain). Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I. Eur Respir J 2012; 40: Suppl. 56, 2890

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 356s
Year: 2007

Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 199s
Year: 2006

Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 113s
Year: 2004

Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Tiotropium bromide: Efficacy and safety in complex treatment of COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 286s
Year: 2003

Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012

Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations)
Source: Annual Congress 2007 - Primary care respiratory problems
Year: 2007


ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study
Source: Annual Congress 2007 - New drugs for COPD
Year: 2007


Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 72s
Year: 2001

Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011